Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1

Mostrar otras versiones (1)

OBJECTIVES: Recent 2022 SARS-CoV-2 Omicron variants, have acquired resistance to most neutralizing anti-Spike monoclonal antibodies authorized, and the BQ.1.* sublineages are notably resistant to all authorized monoclonal antibodies. Polyclonal antibodies from individuals both vaccinated and recentl...

Descripción completa

Detalles Bibliográficos
Autores principales: Sullivan, David J, Franchini, Massimo, Senefeld, Jonathon W., Joyner, Michael J., Casadevall, Arturo, Focosi, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727765/
https://www.ncbi.nlm.nih.gov/pubmed/36482971
http://dx.doi.org/10.1101/2022.11.25.517977

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727765/
https://www.ncbi.nlm.nih.gov/pubmed/36482971
http://dx.doi.org/10.1101/2022.11.25.517977

Ejemplares similares